Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of Cellular Immune Response to Adeno-Associated Virus-Based Gene Therapy.
Gorovits B, Azadeh M, Buchlis G, Fiscella M, Harrison T, Havert M, Janetzki S, Jawa V, Long B, Mahnke YD, McDermott A, Milton M, Nelson R, Vettermann C, Wu B. Gorovits B, et al. Among authors: mahnke yd. AAPS J. 2023 Apr 26;25(3):47. doi: 10.1208/s12248-023-00814-5. AAPS J. 2023. PMID: 37101079 Free PMC article. Review.
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.
Hu-Lieskovan S, Bhaumik S, Dhodapkar K, Grivel JJB, Gupta S, Hanks BA, Janetzki S, Kleen TO, Koguchi Y, Lund AW, Maccalli C, Mahnke YD, Novosiadly RD, Selvan SR, Sims T, Zhao Y, Maecker HT. Hu-Lieskovan S, et al. Among authors: mahnke yd. J Immunother Cancer. 2020 Dec;8(2):e000705. doi: 10.1136/jitc-2020-000705. J Immunother Cancer. 2020. PMID: 33268350 Free PMC article.
Correction to: Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients.
Battaglia A, Buzzonetti A, Fossati M, Scambia G, Fattorossi A, Madiyalakan MR, Mahnke YD, Nicodemus C. Battaglia A, et al. Among authors: mahnke yd. Cancer Immunol Immunother. 2020 Jul;69(7):1389. doi: 10.1007/s00262-020-02537-4. Cancer Immunol Immunother. 2020. PMID: 32219502 Free PMC article.
Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients.
Battaglia A, Buzzonetti A, Fossati M, Scambia G, Fattorossi A, Madiyalakan MR, Mahnke YD, Nicodemus C. Battaglia A, et al. Among authors: mahnke yd. Cancer Immunol Immunother. 2020 Mar;69(3):383-397. doi: 10.1007/s00262-019-02456-z. Epub 2020 Jan 3. Cancer Immunol Immunother. 2020. PMID: 31897661 Free PMC article. Clinical Trial.
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.
Garfall AL, Maus MV, Hwang WT, Lacey SF, Mahnke YD, Melenhorst JJ, Zheng Z, Vogl DT, Cohen AD, Weiss BM, Dengel K, Kerr ND, Bagg A, Levine BL, June CH, Stadtmauer EA. Garfall AL, et al. Among authors: mahnke yd. N Engl J Med. 2015 Sep 10;373(11):1040-7. doi: 10.1056/NEJMoa1504542. N Engl J Med. 2015. PMID: 26352815 Free PMC article. Clinical Trial.
OMIP-029: Human NK-cell phenotypization.
Mahnke YD, Beddall MH, Roederer M. Mahnke YD, et al. Cytometry A. 2015 Nov;87(11):986-8. doi: 10.1002/cyto.a.22728. Epub 2015 Jul 30. Cytometry A. 2015. PMID: 26228006 Free article. Review. No abstract available.
Chimeric antigen receptor T cells for sustained remissions in leukemia.
Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA. Maude SL, et al. Among authors: mahnke yd. N Engl J Med. 2014 Oct 16;371(16):1507-17. doi: 10.1056/NEJMoa1407222. N Engl J Med. 2014. PMID: 25317870 Free PMC article. Clinical Trial.
27 results